QuantuMDx’ Rapid, Sensitive SARS-CoV-2 PCR Test Validated for Use
QuantuMDx Group Limited, a UK-based life sciences company developing transformational point-of-care molecular diagnostics, today announces its sensitive SARS-CoV-2 assay for laboratory use has been validated by NHS Test and Trace.
Key conclusions from the report verify QuantuMDx’s performance claims, confirming that the test has a Limit of Detection of less than 500 copies/ml, clinical sensitivity of 98.9% and clinical specificity of 99.1%, making it one of the most sensitive tests on the market. Furthermore, its performance fulfils the requirements of the MHRA’s Target Product Profile (TPP) for Laboratory-Based SARS-CoV-2 Viral Detection tests, essential for NHS Test & Trace’s validation process.
QuantuMDx’s SARS-CoV-2 assay, which delivers a result in approximately 70 minutes, following preparation and extraction of RNA is a real-time reverse transcriptase PCR (rtRT-PCR) test that has been developed using advanced bioinformatics to maximise performance. The assay has been designed with the most up-to-date sequence information available to ensure 100% coverage of all known SARS-CoV-2 sequences. This involves in silico analysis against The GISAID database at least fortnightly, or whenever new variants of concern are identified. The sensitive test targets three unique SARS-CoV-2 specific genomic loci; the S and N genes and the Orf1ab region. The assay can run on multiple open real-time PCR platforms, both high and low throughput. Furthermore, the assay reagents are lyophilised in a single vial, eliminating multiple pipetting steps, enabling convenient shipping and longer shelf-life.
Jonathan O’Halloran, Co-founder and Chief Executive Officer of QuantuMDx said: “We are pleased to see the publication of this report which confirms our test to be a sensitive and specific laboratory assay and underlines the quality of our science and development process. The progress that has been made with diagnostics, testing, and the emergence of an approved vaccine this year, is incredible. Despite this, however, we must not rest and must continue to fight this pandemic.”
QuantuMDx is also independently validating the use of the test without the need for RNA extraction, running the RT-PCR test directly from swabs. Furthermore, the company is validating the test for use with additional specimen types, including saliva.
In addition to having developed a SARS-CoV-2 test for laboratories, QuantuMDx continues preparations for scale- up and manufacture of its Q-POC™ rapid point-of-care testing device which would allow the sensitivity of molecular testing to move beyond the laboratory. The company is currently translating its SARS-CoV-2 detection assay to the Q-POC™ platform, as a respiratory panel for the detection and differentiation of SARS-SoV-2, Influenza A & B. Using swab samples, a Q-POC™ test could provide a result in approximately 30 minutes, at the point-of-need.
QuantuMDx Group is an ambitious company with a global vision of empowering the world to control and eradicate disease by making transformative, quality point-of-care diagnostic technologies universally accessible. QuantuMDx has operations and strategic partnerships in the United States, Asia, Australasia, Europe and Africa – keeping it at the forefront of molecular diagnostics. For more information go to: www.quantumdx.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SAMSUNG-ELECTRONICS4.3.2021 10:15:10 CET | Press release
Samsung Electronics, Mastercard and Samsung Card Sign MoU for Fingerprint Biometric Payment Card
IDEMIA4.3.2021 09:02:10 CET | Press release
IDEMIA to Participate in the UK Government’s Digital Identity Pilot
ADVA4.3.2021 09:02:10 CET | Press release
VicTrack transforms rail and government infrastructure with ADVA FSP 3000
ARTHUR-D.-LITTLE4.3.2021 09:02:09 CET | Press release
Flagship Report From Arthur D. Little Urges Telcos to Accelerate Growth by Embracing New Services and Reconfiguring Network Assets
GALDERMA4.3.2021 08:59:05 CET | Press release
Galderma Continues Global Growth Ambition With Sculptra® (injectable poly-L-lactic Acid) Re-launch in Europe
CA-OPENGATE-CAPITAL4.3.2021 08:02:15 CET | Press release
OpenGate Capital Portfolio Company, SMAC, Completes Sale of AXTER
EXSCIENTIA4.3.2021 08:02:15 CET | Press release
Exscientia Completes $100 million Series C Financing Round With BlackRock Funds
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom